Fenotipos en la EPOC

Revista de Patologia Respiratoria

Volumn 12, Issue SUPPL.2, 2009, Pages 176-182

  Ramos, P De Lucas ^a   Martín, López ^a   Lucero, S ^a   Morales, C Juarez ^a   González Moro, Rodríguez ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79851495418     PISSN: 15769895     EISSN: 2173920X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol. 2008; 44: 271-81.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. www.goldcopd.com.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932-46.
4. Terminology, definitios and classification of chronic pulmonary emphysema and related conditions. A report of the conclusions of a CIBA guest symposium. Thorax. 1959; 14: 286-99.
5. Pulmonary terms and symbols. Areport of the ACCP-ATS Joint Committee on Pulmonary Nomenclature. Chest 1975; 67: 583-93.
6. Thurlbeck WM. Aspects of chronic airflow obstruction. Chest. 1977; 72: 341-49.
7. Dornhorst AC. Respiratory insufficiency. Lancet. 1955; 268: 1183-7.
8. García-Aymerich J, Agustí A, Barberà JA, Belda J, Farrero E, Ferrer A, et al. en nombre del Grupo de Trabajo sobre la Caracterización Fenotípica y Evolución de la Enfermedad Pulmonar Obstructiva Crónica (PAC-COPD). Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch Bronconeumol. 2009; 45: 129-38.
9. Hogg JC, Maclem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Eng J Med. 1968; 278: 1355-60
10. Cosio MG, Ghezzi H, Higg JC, Mackem PT. The relations between structural changes in small airways and pulmonary function tests. N Engl J Med. 1978; 298: 1277-81.
11. Kim WD, Eidelman D, Izquierdo JL, Ghezzo H, Saetta M, Cosío MG. Centrilobular and Panlobular emphysema in smokers. Two Distinct morphological and functional entities. Am Rev Respir Dis. 1991; 144: 1385-90.
12. Saetta M, Kim WD, Izquierdo JL, Ghezzo H, Cosío MG. Extent of centrilobular and panacinar emphysema in smokers'lungs: pathological and mechanical implications. Eur Respir J. 1994; 7: 664-671
13. Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 2645-53.
14. Miniati M, Monti S, Stolk J, Mirarchi G, Falaschi F, Rabinovich R, et al. Value of chest radiography in phenotyping chronic obstructive pulmonary disease. Eur Respir J. 2008; 31: 509-15.
15. Cerveri I, Dore R, Corsico A, Zoia MC, Pellegrino R, Brusasco V, et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest. 2004; 125: 1714-8.
16. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax. 2006; 61:1037-40.
17. Vignola AM, Paganin F, Capieu L, Scichilone N, Bellia M, Maakel L, et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J. 2004; 24: 910-7.
18. Camiciottoli G, Bartolucci M, Maluccio NM, Moroni C, Mascalchi M, Giuntini C, et al. Spirometrically gated high-resolution CT findings in COPD: lung attenuation vs lung function and dyspnea severity. Chest. 2006; 129: 558-64.
19. Kitaguchi Y, Fujimoto K, Kubo K, Honda T. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 2006; 100: 1742,1750.
20. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986; 133: 14-20.
21. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160: 542-9.
22. Casanova C, Cote C,,DeTorres JP, Aguirre-Jaime A, Marín JM, Pinto-PlataV, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591-7.
23. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med. 1987; 317: 1309-14.
24. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:1267-71.
25. Castaldi PJ, Hersh CP, Reilly JJ, Silverman EK. Genetic associations with hypoxemia and pulmonary arterial pressure in COPD. Chest 2009; 135: 737-44.
26. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5- year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434-40.
27. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984; 85: 751-8.
28. Burgel PR, Nesme-Meyer P, Chánez P, Caillaud D, Carré Ph, Pérez Th, Roche N. Cough and sputum production are associated with frequent exacerbations and hospitalization in COPD subjects. Chest. 2009; 135: 975-82
29. Domingo-Salvany, Lamarca R, Ferrer M, García-Aymerich J, Alonso J, Félez M, et al. Health-related quality of lifeand mortality inmale patients with chronic obstructive pulmonary disease. Am J Respir Care Med. 2002; 166: 680-5.
30. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a preditor of survival in severe COPD. Eur Respir J. 2004; 23:28-33.
31. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.
32. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925-31.
33. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J COPD. 2009; 4: 245-51.
34. Rutgers SR, Timens W, Tzanakis N, Kauffman HF, Van der Mark TW, Koeter GH, et al. Airway inflammation and hyperresponsiveness toadenosine 50- monophosphate in chronic obstructive pulmonary disease. Clin Exp Allergy. 2000; 30: 657-62.
35. Brightling CE, McKenna S, Hargadon B, Birring SS, Green RH, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasonei n chronic obstructive pulmonary disease. Thorax. 2005; 60: 193-8.
36. Snoeck-Stroband JB, Lapperre TS, Gosman MM, Boezen HM, Timens W, ten Hacken NH, Sont JK, Sterk PJ, Hiemstra PS. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study Group. Eur Respir J. 2008; 31: 70-7.
37. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metanalysis. Thorax. 2004; 59: 574-80.
38. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharm Therap. 2006; 19:189-99.
39. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007; 62:595-601.
40. Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat J, Kotz D, Lima-Passos V, Wouters EFM. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Medical Genetics. 2009; 10: 23.
41. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmoary Disease, inflammation and co-morbidity- a common inflammatory phenotype. Respiratory Research (BMC). 2006; 7: 70.
42. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory disease? Lancer. 2007; 370: 797-9.
43. Lucas-Ramos P, Izquierdo-Alonso JL, Rodríguez-González Moro JM, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M, et al. Asociación de factores de riesgo cardiovascular y EPOC. Resultados de un estudio epidemiológico (estudio ARCE). Arch Bronconeumol. 2008; 238: 233-8.
44. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008; 63: 599-605.
45. Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS. The emphysematous and bronchial types of chronic airways obstruction. Aclinicopathological study of patients in London and Chicago. Lancet. 1966; 87: 830-5.
46. Petty TL. COPD: clinical phenotypes. Pulm Pharcol Therap. 2002; 15: 341-5.
47. Izquierdo JL, Almonacid C, Parra T, Pérez J. Inflamación pulmonar y sistémica en 2 fenotipos de EPOC. Arch Bronconeumol. 2006; 42: 332-7.
48. Paoletto M, Camiciottoli G, Meoni E, Bigazzi F, Cestelli L, Pistolesi M, Marchesi C. Explorativa data analysis techiques and unsupervised clustering methods to support clinicas assessmento of chronic obstructive pulmonary disease (COPD) phenotypes. J Biomed Inform. 2009; 42: 1013-21.
49. Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. COPD phenotype description using principal componets analysis. Respir Research. 2009; 10: 41.
50. Pistolesi M, Camiiciottoli G, Paoetti M. Marmai C, Lavorini F, Meoni E, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med. 2008; 102: 367-76.